| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Tubulin beta-4B chain;Tubulin beta-2 chain;Tubulin beta-2C chain;TUBB4B;TUBB2C; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Gene ID | |
| Host | |
| Immunogen | A synthesized peptide derived from human KA1 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-GRIK4 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 21G22; isotype IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB (as provided in the source record). Boster Bio Anti-KA1 Rabbit Monoclonal Antibody catalog # M09195. Tested in WB application. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: GRIK4 (Tubulin beta-4B chain).
- Antibody format: Monoclonal; clone 21G22; isotype IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
GRIK4 (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. Reported cellular localization context: Cytoplasm, cytoskeleton. Tissue expression notes (as provided): Ubiquitous. .
Research relevance and current trends
- Research context keywords from the source record include: Actin Assembly,Actin, etc.,Cytoskeleton,Cytoskeleton/ECM,Microfilaments,Signal Transduction.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
Workflow ideas (metafield): Validate GRIK4 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect GRIK4 expression by Western blot in cell or tissue lysates, Compare relative GRIK4 levels across experimental conditions (dose/time-course) using antibody-based readouts
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 107 kDa; calculated MW: 49831 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 107 kDa
- Cellular localization (provided): Cytoplasm, cytoskeleton.
- Tissue details (provided): Ubiquitous. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
